Progyny Inc(PGNY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 5:45 PM ET (Korea 9/16 06:45)
Full metrics table
| Index | RUT | P/E | 30.15 | EPS (ttm) | 0.92 | Insider Own | 2.86% | Shs Outstand | 77.4M | Perf Week | 2.25% |
| Market Cap | 2.13B | Forward P/E | 18.26 | EPS next Y | 18.19% | Insider Trans | -2.36% | Shs Float | 74.5M | Perf Month | 5.63% |
| Enterprise Value | 1.92B | PEG | 0.49 | EPS next Q | 0.31 | Inst Own | 103.59% | Short Float | 5.97% | Perf Quarter | 3.16% |
| Income | 0.08B | P/S | 1.62 | EPS this Y | 97.87% | Inst Trans | -2.52% | Short Ratio | 3.72 | Perf Half Y | 59.36% |
| Sales | 1.31B | P/B | 4.74 | EPS next 5Y | 37.58% | ROA | 10.65% | Short Interest | 4.45M | Perf YTD | 8.1% |
| Book/sh | 5.86 | P/C | 8.99 | EPS past 3/5Y | 28.95% 6.78% | ROE | 16.24% | 52W High | -16.04% ($33.06) | Perf Year | 25.44% |
| Cash/sh | 3.09 | P/FCF | 11.94 | Sales past 3/5Y | 17.87% 30.17% | ROIC | 16.53% | 52W Low | 72.42% ($16.10) | Perf 3Y | -18.85% |
| Dividend Est. | - | EV/EBITDA | 16.29 | EPS Y/Y TTM | 57.3% | Gross Margin | 24.57% | Volatility(W/M) | 3.14% 2.82% | Perf 5Y | -54.21% |
| Dividend TTM | - | EV/Sales | 1.46 | Sales Y/Y TTM | 5.54% | Oper. Margin | 8.55% | ATR (14) | 0.85 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.14 | EPS Q/Q | 78.89% | Profit Margin | 6% | RSI (14) | 55.75 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.14 | Sales Q/Q | 5.3% | SMA20 | 5.4% ($26.34) | Beta | 1 | Target Price | $34.42 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/8/6 | SMA50 | -3.21% ($28.68) | Rel Volume | 0.58 | Prev Close | $27.85 |
| Employees | 856 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 1.58% 0.42% | SMA200 | 14.87% ($24.17) | Avg Volume(3M) | 1.20M | Price | $27.76 |
| IPO | 2019/10/25 | Option/Short | Yes/Yes | Trades | 11465 | Volume | 690,703 | Change | -0.32% |
Company
PGNY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US healthcare company that provides fertility and family-building benefits management services for employers. It designs and manages fertility treatment and family-building benefits offered by employers to their employees, operating a benefits platform that combines a specialized medical network, clinical management, and pharmaceutical services. The company has established itself as a specialized benefits administrator focused on fertility benefits.
Over the past 1 year, roughly in the middle
16% below its 1-year high.
PGNY makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +97.9% this year.
Tap to view numbers
The price looks about right
Trading at 30.1 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -18.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 103.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
TCV 0.03%
ABLS 0.02%
XHS 0.02%
SIXS 0.02%
FSGS 0.02%It ranks #4 in the industry
Based on market cap of $2B.
PGNY $2B PER 30.1
UNH $337B PER 24.2
CVS $121B PER 24.9
ELV $91B PER 18.6
FAQ
What kind of company is PGNY?
PGNY belongs to the Healthcare sector and operates in the Healthcare Plans industry.
What is the market cap of PGNY?
The market cap of PGNY is approximately $2.1B, ranking 2,036 within its sector.
What is the P/E ratio of PGNY?
PGNY has a P/E ratio of approximately 30.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PGNY?
PGNY has recorded a 52-week high of $33.06 and a low of $16.10.
